Maegim한국어

비보존 제약

082800KOSDAQSector: Pharma & Biotech
₩2,420 1.47%Market cap ₩146.9BAs of Jul 21, 2026 close · updated once daily
F
Grade F22.9 ptsTop 94% of 2,523 stocks
Financial strength
18.6
Growth momentum
21.9
Price attractiveness
28.5

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

18.6
How much debt does it carry relative to equity?
Debt-to-equity ratio
127.7%
Below median · Top 83.9% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
43.2%
Below median · Top 94.9% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-32.3%
Below median · Top 64.4% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-44.6%
Below median · Top 82.3% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

21.9
How much did revenue grow in a year?
Revenue growth (YoY)
-32.3%
Below median · Top 92.9% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
0.2%
Below median · Top 67.9% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-771.7%
Below median · Top 97.5% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-3.4%
Below median · Top 54% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

28.5
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 84.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
2.02x
Below median · Top 58.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15